Aspire Biopharma Holdings Inc.
ASBP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ASBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ASBP
Aspire Biopharma Holdings Inc. (ASBP) is a pre-revenue biopharmaceutical company developing novel therapies for heart attacks and strokes, with a lead candidate of high-dose sublingual aspirin. The company has no approved products, has incurred losses since inception, and faces significant clinical and financial uncertainties.
Key risk: No approved products or revenue
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Aspire Biopharma Holdings Inc..
Aspire Biopharma Holdings Inc. (ASBP) is a pre-revenue biopharmaceutical company developing novel therapies for heart attacks and strokes, with a lead candidate of high-dose sublingual aspirin. The company has no approved products, has incurred losses since inception, and faces significant clinical and financial uncertainties.
- No products approved for commercial sale and no revenue from product sales to date [sec · filed 2026-02-17].
- Cash & equivalents of $12.2M as of 2026-06-30 [sec].
- Net loss of $1.3M for the period ended 2026-06-30 [sec].
- Lead product candidate is high-dose sublingual aspirin for heart attacks/strokes [sec · filed 2025-12-03].
- Company expects to continue incurring significant losses for the foreseeable future [sec · filed 2026-02-17].
What works
- The company is developing a novel targeted therapy (high-dose sublingual aspirin) for acute cardiovascular events, addressing a large unmet medical need [sec · filed 2025-12-03].
- The company has cash of $12.2M as of 2026-06-30 to fund near-term operations [sec].
What to weigh
- The company has no approved products, no product revenue, and an accumulated deficit reflected in negative shareholders' equity of -$1.5M as of 2026-06-30 [sec].
- Clinical development is lengthy, expensive, and uncertain; earlier results may not predict future trial outcomes [sec · filed 2026-02-17].
- The company relies on third-party CROs and clinical sites, with limited control over their performance, risking delays [sec · filed 2026-02-17].
- The scientific evidence for high-dose sublingual aspirin is preliminary and limited [sec · filed 2025-12-03].
From the filings
Quoted directly from source documents.
No approved products or product revenue
“We have no products approved for commercial sale and have not generated any revenue from product sales to date”
SEC filings · February 17, 2026
Lead product candidate is high-dose sublingual aspirin
“We expect to initially develop our lead product candidate, high-dose sublingual aspirin,”
SEC filings · December 3, 2025
Preliminary scientific evidence
“The scientific evidence to support the feasibility of developing product candidates based on our high-dose sublingual aspirin is preliminary and limited.”
SEC filings · December 3, 2025
Reliance on third parties and risk of delays
“we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance.”
SEC filings · February 17, 2026
Risks & what to watch (4)›
Key risks
- No approved products or revenue — Company has no commercial products and no product sales revenue; expects continued losses [sec · filed 2026-02-17].
- Clinical trial uncertainty
- Dependence on third-party CROs
- Preliminary scientific basis
What to watch
- Progress and enrollment in clinical trials for high-dose sublingual aspirin [sec · filed 2026-02-17].
- Cash burn rate and need for additional financing given $12.2M cash as of 2026-06-30 [sec].
- Any regulatory feedback or clinical holds from the FDA [sec · filed 2026-02-17].
- Ability to manage CRO relationships and avoid trial delays [sec · filed 2026-02-17].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Aspire Biopharma Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aspire Biopharma Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
17.8 months
D/E 0.15 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
10
Total value held
$150K
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 76,955 | $79K |
| geode capital management, llc | 43,384 | $45K |
| vanguard capital management llc | 15,718 | $16K |
| toronto dominion bank | 5,000 | $5K |
| vanguard fiduciary trust co | 2,856 | $3K |
| citigroup inc | 1,846 | $2K |
| osaic holdings, inc. | 2 | $2 |
| caitong international asset management co., ltd | 1 | $1 |
| avion wealth | 1,352 | $1 |
| sbi securities co., ltd. | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 17.3%
- Days to cover
- 0.0
- Shares short
- 27,382
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ASBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Aspire Biopharma Holdings Inc.?
Aspire Biopharma Holdings Inc. (ASBP) is a pre-revenue biopharmaceutical company developing novel therapies for heart attacks and strokes, with a lead candidate of high-dose sublingual aspirin. The company has no approved products, has incurred losses since inception, and faces significant clinical and financial uncertainties.
What is Aspire Biopharma Holdings Inc.'s lead drug candidate?
Aspire Biopharma Holdings Inc.'s most advanced tracked candidate is Instaprin (Preclinical) for suspected acute myocardial infarction.
Who is the CEO of Aspire Biopharma Holdings Inc.?
Mr. Kraig T. Higginson is the chief executive officer of Aspire Biopharma Holdings Inc. (ASBP).
Where is Aspire Biopharma Holdings Inc. headquartered?
Aspire Biopharma Holdings Inc. (ASBP) is headquartered in Estero, FL, United States.
What therapeutic areas does Aspire Biopharma Holdings Inc. focus on?
Aspire Biopharma Holdings Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.